Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In its latest biosimilar trends report, Amgen makes the case for purchasing biosimilars from a company with a track record for quality biologics manufacturing – presumably, one such as its own.


Related Content

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Drug Shortage Analysis Puts FDA At Loggerheads With GAO


Related Companies